GlassScriptPhysician profile
David T Park
NPI 1275766453
$14,066.22
in general payments reported to CMS, 2019-2025
69 companies · $1,973 in 2025
The $1,973 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,477 · 2020: $1,178 · 2021: $805 · 2022: $2,125 · 2023: $2,421 · 2024: $3,087 · 2025: $1,973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,480.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,842.85 | 2020-2025 | |
| Ucb, INC. | $929.58 | 2019-2025 | Nayzilam, Briviact, Rystiggo |
| Sunovion Pharmaceuticals INC. | $658.92 | 2019-2022 | |
| Lilly USA, LLC | $638.26 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Sk Life Science, INC. | $612.24 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $606.92 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Mdd US Operations, LLC | $490.20 | 2020-2025 | Gocovri, Gocovri, Apokyn |
| Amneal Pharmaceuticals LLC | $468.65 | 2020-2025 | Rytary, Ongentys, Ongentys 50mg Capsules 30 |
| Upsher-Smith Laboratories LLC | $462.88 | 2019-2023 | |
| Eisai INC. | $395.61 | 2019-2025 | |
| Genentech USA, INC. | $377.05 | 2019-2024 | Ocrevus |
| Acorda Therapeutics, INC | $374.81 | 2019-2024 | Inbrija |
| Acadia Pharmaceuticals INC | $353.35 | 2019-2025 | Nuplazid |
| Sumitomo Pharma America, INC. | $343.38 | 2023-2024 | Aptiom |
| Biogen, INC. | $328.61 | 2019-2024 | Leqembi, Qalsody, Skyclarys |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.